for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover   Journal of Clinical and Experimental Hepatology
  [SJR: 0.142]   [H-I: 3]   [1 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 0973-6883
   Published by Elsevier Homepage  [2799 journals]
  • Role of Pentoxifylline and Steroids for Alcoholic Hepatitis – Has
           the last word been said'
    • Authors: Shalimar
      Pages: 170 - 172
      Abstract: J Hepatol 2014;61:792–798.
      Citation: Journal of Clinical and Experimental Hepatology 5, 2 (2015)
      PubDate: 2015-06
      DOI: 10.1016/j.jceh.2015.06.005
      Issue No: Vol. 5, No. 2 (2015)
  • Hepatobiliary Quiz—14 (2015)
    • Authors: Sahaj Rathi; Radha K. Dhiman
      Pages: 173 - 174
      Citation: Journal of Clinical and Experimental Hepatology 5, 2 (2015)
      PubDate: 2015-06
      DOI: 10.1016/j.jceh.2015.06.006
      Issue No: Vol. 5, No. 2 (2015)
  • Hepatobiliary Quiz (Answers)—14 (2015)
    • Authors: Sahaj Rathi; Radha K. Dhiman
      Pages: 175 - 178
      Abstract: Ammonia is primarily metabolized in the liver by the urea cycle under normal conditions. The leftover ammonia is detoxified by the enzyme glutamate synthetase (GS), which converts the ammonia into glutamine. GS is found in the hepatocytes surrounding the hepatic veins, muscle cells and astrocytes.1,2 Within the CNS, GS is located exclusively within the astrocytes. Thus, these cells bear the brunt of the toxic effects of ammonia, in turn leaving the neurons completely unaffected by the exposure.3–5 In patients with cirrhosis, astrocytes exhibit features of Alzheimer Type II astrocytosis, which include nuclear swelling, enlargement of cytoplasm and margination of chromatin.
      Citation: Journal of Clinical and Experimental Hepatology 5, 2 (2015)
      PubDate: 2015-06
      DOI: 10.1016/j.jceh.2015.06.007
      Issue No: Vol. 5, No. 2 (2015)
  • Indian National Association for Study of the Liver (INASL) Guidance for
           Antiviral Therapy Against HCV Infection in 2015
    • Authors: Pankaj Puri; Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya, Radha K. Dhiman, Shiv K. Sarin, Shivaram P. Singh, Yogesh K. Chawla, Rakesh Aggarwal, Deepak Amarapurkar, Anil Arora, Vinod K. Dixit, Ajit Sood, Samir Shah, Ajay Duseja, Dharmesh Kapoor, Shalimar, Kaushal Madan, Gaurav Pande, Aabha Nagral, Premashis Kar, Abraham Koshy, Amarender S. Puri, C.E. Eapen, Sandeep Thareja
      Abstract: Overall prevalence of HCV infection in India has been estimated to be approximately 1.3% in the general population. Recent introduction of sofosbuvir in India at a relatively affordable price has led to great optimism about prospects of cure for these patients. This drug is likely to form the backbone of current and future treatment regimes for HCV infection, displacing pegylated interferon. Availability of directly acting antiviral drugs (DAAs) has necessitated revision of INASL guidelines for the treatment of HCV published in 2014, as has happened across the world.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-09-30
      DOI: 10.1016/j.jceh.2015.09.002
  • Risk Factors Associated With Non-Alcoholic Fatty Liver Disease in Indians:
           A Case–Control Study
    • Authors: Shivaram P. Singh; Ayaskanta Singh, Debasis Misra, Bijay Misra, Girish K. Pati, Manas K. Panigrahi, Sanjib K. Kar, Pallavi Bhuyan, Kaumudee Pattnaik, Chudamani Meher, Omprakash Agrawal, Niranjan Rout, Manoroma Swain, Palok Aich
      Abstract: NAFLD has today emerged as the leading cause of liver disorder. There is scanty data on risk factors associated with NAFLD emanating from India. The present study was conducted to identify the risk factors associated with NAFLD.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-09-29
      DOI: 10.1016/j.jceh.2015.09.001
  • Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on
           Oral Anticoagulation and Elevated International Normalized Ratio
    • Authors: Harshad Devarbhavi; Arvind R. Murali
      Abstract: Anticoagulation is the standard of care in patients with Budd-Chiari Syndrome (BCS). Ascites is a common symptom in patients with BCS. Often such patients require paracentesis while taking oral anticoagulation concurrently. It is unclear whether paracentesis leads to increased bleeding in such patients or whether anticoagulation has to be temporarily suspended. We describe our experience with paracentesis in patients with BCS taking oral anticoagulation.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-09-15
      DOI: 10.1016/j.jceh.2015.08.004
  • Randomized Controlled Trial Comparing the Efficacy of Terlipressin and
           Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin
           in Hepatorenal Syndrome
    • Authors: Siddharth Srivastava; Shalimar, Sreenivas Vishnubhatla, Shyam Prakash, Hanish Sharma, Bhaskar Thakur, Subrat K. Acharya
      Abstract: Terlipressin with albumin is recommended in hepatorenal syndrome (HRS). Terlipressin is expensive and not licensed in many countries. Alternative therapy is necessary. We compared the efficacy of terlipressin and albumin with concurrent low-dose dopamine, furosemide, and albumin in HRS.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-09-10
      DOI: 10.1016/j.jceh.2015.08.003
  • Acute-On-Chronic Liver Failure (ACLF) in Coastal Eastern India: “A
           Single-Center Experience”
    • Authors: Girish Kumar Pati; Ayaskanta Singh, Bijay Misra, Debasis Misra, Haribhakti Seba Das, Chittaranjan Panda, Shivaram Prasad Singh
      Abstract: Acute-On-Chronic liver failure (ACLF) is an emerging entity. The present study was undertaken to analyze the clinical profile and natural course of ACLF patients.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-09-01
      DOI: 10.1016/j.jceh.2015.08.002
  • Magnetic Resonance Imaging: Principles and Techniques: Lessons for
    • Authors: Vijay P.B. Grover; Joshua M. Tognarelli, Mary M.E. Crossey, I. Jane Cox, Simon D. Taylor-Robinson, Mark J.W. McPhail
      Abstract: The development of magnetic resonance imaging (MRI) for use in medical investigation has provided a huge forward leap in the field of diagnosis, particularly with avoidance of exposure to potentially dangerous ionizing radiation. With decreasing costs and better availability, the use of MRI is becoming ever more pervasive throughout clinical practice. Understanding the principles underlying this imaging modality and its multiple applications can be used to appreciate the benefits and limitations of its use, further informing clinical decision-making.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-08-28
      DOI: 10.1016/j.jceh.2015.08.001
  • Management Patterns of Hepatic Encephalopathy: A Nationwide Survey in
    • Authors: Praveen Sharma; Barjesh Chander Sharma
      Abstract: Hepatic encephalopathy (HE) is a common complication of cirrhosis. There is no standard practice for its management. This survey was done to determine the diagnostic and therapeutic practices of physicians treating patients with HE in patients with cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-08-19
      DOI: 10.1016/j.jceh.2015.06.008
  • Attack of the Clone: HCC Tract Seeding Following RFA
    • Authors: Deepak N. Amarapurkar; Mrudul V. Dharod, Deepak Chhabra
      Abstract: A 42-year-old obese male, accidentally detected to be hepatitis B surface antigen (HBsAg) positive, presented to us in 2006. Patient was negative for antibodies to hepatitis C virus (anti-HCV) and hepatitis B envelope antigen (HBeAg) and had hepatitis B (HBV) DNA viral load of 525,073IU/ml. He had mild thrombocytopenia, mildly elevated serum transaminases, and hypoalbuminemia. Ultrasonography revealed two hypoechoic lesions in the right lobe of liver. Serum alpha-fetoprotein (AFP) levels were 4.99IU/ml whereas upper gastrointestinal endoscopy revealed small esophageal varices.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-08-06
      DOI: 10.1016/j.jceh.2015.07.204
  • Plasma Lipid Profiling in a Rat Model of Hepatocellular Carcinoma:
           Potential Modulation Through Quinolone Administration
    • Authors: Mohamed I.F. Shariff; Joshua M. Tognarelli, Matthew R. Lewis, Elizabeth J. Want, Fatma El Zahra Mohamed, Nimzing G. Ladep, Mary M.E. Crossey, Shahid A. Khan, Rajiv Jalan, Elaine Holmes, Simon D. Taylor-Robinson
      Abstract: The primary aim of this study was to characterise the blood metabolic profile of hepatocellular carcinoma (HCC) in a rat model, and the secondary aim was to evaluate the effect of the quinolone, norfloxacin on metabolic profiles and exploring the role that gut sterilisation may have on HCC development.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-07-29
      DOI: 10.1016/j.jceh.2015.07.205
  • Animal Models Correlating Immune Cells for the Development of NAFLD/NASH
    • Authors: Srikanth Iyer; Pramod Kumar Upadhyay, Subeer S. Majumdar, Perumal Nagarajan
      Abstract: This review mainly elaborates on the animal models available for understanding the pathogenesis of the second hit of non-alcoholic fatty liver disease (NAFLD) involving immune system. This is known to be a step forward from simple steatosis caused during the first hit, which leads to the stage of inflammation followed by more serious liver conditions like non-alcoholic steatohepatitis (NASH) and cirrhosis. Immune-deficient animal models serve as an important tool for understanding the role of a specific cell type or a cytokine in the progression of NAFLD.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-07-23
      DOI: 10.1016/j.jceh.2015.06.004
  • Addition of Somatostatin After Successful Endoscopic Variceal Ligation
           does not Prevent Early Rebleeding in Comparison to Placebo: A Double Blind
           Randomized Controlled Trial
    • Authors: Ashish Kumar; Sanjeev K. Jha, Vibhu V. Mittal, Praveen Sharma, Barjesh C. Sharma, Shiv K. Sarin
      Abstract: Efficacy of endoscopic sclerotherapy in controlling acute variceal bleeding is significantly improved when vasoactive drug is added. Endoscopic variceal ligation (EVL) is superior to sclerotherapy. Whether efficacy of EVL will also improve with addition of somatostatin is not known. We compared EVL plus somatostatin versus EVL plus placebo in control of acute variceal bleeding.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-07-08
      DOI: 10.1016/j.jceh.2015.06.001
  • Complications of Catheter Drainage for Amoebic Liver Abscess
    • Authors: Navneet Sharma; Harpreet Kaur, Naveen Kalra, Ashish Bhalla, Susheel Kumar, Virendra Singh
      Abstract: Per-cutaneously inserted catheter drainage is an accepted treatment modality for a large amoebic liver abscess. Complications that can arise are; secondary infection, bleeding into the abscess cavity, inadvertent catheter misplacement into the IVC and rupture of abscess with spillage into the peritoneal cavity. We report a case of a large amoebic liver abscess that presented with complications related to per-cutaneously inserted catheter drainage.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-07-04
      DOI: 10.1016/j.jceh.2015.06.003
  • Epidemiology of Liver Cirrhosis
    • Authors: Cristina Stasi; Caterina Silvestri, Fabio Voller, Francesco Cipriani
      Abstract: Liver cirrhosis is a major public health problem and a significant source of morbidity and mortality that is preventable and underestimated.1 It represents the main indication for liver transplantation in both United States and Europe.2
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-06-25
      DOI: 10.1016/j.jceh.2015.06.002
  • Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma:
           Correlation with Glucose Transporters and p53 Expression
    • Abstract: Hepatocellular Carcinoma (HCC) is one of most lethal cancers worldwide. The prognosis is very poor and therapeutic options are limited. The aim of this study was to determine the correlation of the [18F]FDG uptake profile of three HCC cell lines with p53 and glucose transporters (GLUTs) 1, 2, 3, 5 and 12 expression and with the glucose level present in the cell culture medium.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-06-24
      DOI: 10.1016/j.jceh.2015.05.003
  • HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With
           Chronic Hepatitis B Virus Infection
    • Authors: Sundeep K. Goyal; Ashok K. Jain, Vinod K. Dixit, Suneet K. Shukla, Mohan Kumar, Jayant Ghosh, Arttrika Ranjan, Neha Gupta, Manish Tripathi
      Abstract: Preliminary data suggests lower serum hepatitis B surface antigen level is associated with more severe liver fibrosis in HBeAg positive patients. We evaluated the association of HBsAg level with biochemical, virological, and histological features in asymptomatic patients with chronic HBV infection.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-06-05
      DOI: 10.1016/j.jceh.2015.04.008
  • Hepatitis C Virus (HCV) Infection in Patients with End Stage Renal
           Disease: A Study from a Tertiary Care Centre in India
    • Authors: Anil Arora; Naresh Bansal, Praveen Sharma, Vikas Singla, Varun Gupta, Pankaj Tyagi, Manish Malik, Ashish Kumar
      Abstract: Hepatitis C Virus (HCV) infection is common in patients with end stage renal disease (ESRD) and is an important cause of liver disease. We describe the demographic, clinical and biochemical profile of these patients from a tertiary care center of north India.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-05-15
      DOI: 10.1016/j.jceh.2015.04.004
  • Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese
           Male Mice
    • Authors: Shigeru Nakano; Kenji Katsuno, Masayuki Isaji, Tatsuya Nagasawa, Benjamin Buehrer, Susan Walker, William O. Wilkison, Bentley Cheatham
      Abstract: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are serious conditions and are being diagnosed at an increased rate. The etiology of these hepatic disorders is not clear but involves insulin resistance and oxidative stress. Remogliflozin etabonate (Remo) is an inhibitor of the sodium glucose-dependent renal transporter 2 (SGLT2), and improves insulin sensitivity in type 2 diabetics. In the current study, we examined the effects of Remo in a diet-induced obese mouse model of NAFLD.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-04-27
      DOI: 10.1016/j.jceh.2015.02.005
  • Isolation and Expansion of Hepatic Stem-like Cells from a Healthy Rat
           Liver and their Efficient Hepatic Differentiation of under Well-defined
           Vivo Hepatic like Microenvironment in a Multiwell Bioreactor
    • First page: 107
      Abstract: Currently, undifferentiated cells are found in all tissue and term as local stem cells which are quiescent in nature and less in number under normal healthy conditions but activate upon injury and repair the tissue or organs via automated activating mechanism. Due to very scanty presence of local resident somatic local stem cells in healthy organs, isolation and expansion of these adult stems is an immense challenge for medical research and cell based therapy. Particularly organ like liver, there is an ongoing controversy about existence of liver stem cells.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-06-17
      DOI: 10.1016/j.jceh.2015.03.003
  • Rapid Reversal of Liver Steatosis With Life Style Modification in Highly
           Motivated Liver Donors
    • Authors: Narendra S. Choudhary; Neeraj Saraf, Sanjiv Saigal, Dheeraj Gautam, Lipika Lipi, Amit Rastogi, Sanjay Goja, Palat B. Menon, Prashant Bhangui, Sumana K. Ramchandra, Arvinder S. Soin
      First page: 123
      Abstract: Liver steatosis is the leading cause of donor rejection in living donor liver transplantation. Rapid weight loss is difficult to achieve in a short period of time, moreover it has been thought to worsen liver histology.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-05-06
      DOI: 10.1016/j.jceh.2015.04.002
  • Online-to-print Lags and Baseline Number of Citations in 5 Science
           Citation Index Journals Related to Liver Diseases (2013–2014)
    • Authors: Xingshun Qi; Hongyu Li, Xu Liu, Wenda Xu, Ming Bai, Xiaozhong Guo
      First page: 127
      Abstract: To analyze the length of online-to-print lags in 5 science citation index (SCI) journals related to liver diseases and their effect on the number of citations at the date of print publication.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-04-30
      DOI: 10.1016/j.jceh.2015.04.003
  • Most Patients of Hepatitis C Virus Infection in India Present Late for
           Interferon-Based Antiviral Treatment: An Epidemiological Study of 777
           Patients from a North Indian Tertiary Care Center
    • Authors: Varun Gupta; Ashish Kumar, Praveen Sharma, Naresh Bansal, Vikas Singla, Anil Arora
      First page: 134
      Abstract: Interferon-based antiviral therapy is offered only to those HCV patients who have either chronic hepatitis or early cirrhosis. Advanced cirrhotics do not tolerate interferon-based therapy. Since HCV is asymptomatic in early stages and usually presents late, the eligibility for interferon-based therapy is thus limited. There are scarce studies from India, which looked specifically the eligibility of interferon-based therapy in HCV patients.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-06-13
      DOI: 10.1016/j.jceh.2015.05.001
  • The Riddle of Nonalcoholic Fatty Liver Disease: Progression From
           Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis
    • Authors: Mithun Sharma; Shasikala Mitnala, Ravi K. Vishnubhotla, Rathin Mukherjee, Duvvur N. Reddy, Padaki N. Rao
      First page: 147
      Abstract: Nonalcoholic fatty liver (NAFL) is an emerging global epidemic which progresses to nonalcoholic steatohepatitis (NASH) and cirrhosis in a subset of subjects. Various reviews have focused on the etiology, epidemiology, pathogenesis and treatment of NAFLD. This review highlights specifically the triggers implicated in disease progression from NAFL to NASH. The integrating role of genes, dietary factors, innate immunity, cytokines and gut microbiome have been discussed.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-04
      DOI: 10.1016/j.jceh.2015.02.002
  • Primary Hepatic Burkitt Lymphoma: A Bizarre Site and Triumph Tale
    • Authors: Gaurang Modi; Irappa Madabhavi, Apurva Patel, Swaroop Revannasiddaiah, Asha Anand, Harsha Panchal, Sonia Parikh, Krunal Baldaniya
      First page: 159
      Abstract: Primary hepatic Burkitt lymphoma (PHBL) is an extremely rare form extra nodal lymphoma and till now only 11 case reports have been found in the literature. We are reporting an adult female with primary hepatic Burkitt's lymphoma, who achieved complete remission after 5 months of combination chemotherapy containing vincristine, cyclophosphamide, doxorubicin, methotrexate, prednisolone and intrathecal chemotherapy. She is under regular follow up at our institute.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-05-29
      DOI: 10.1016/j.jceh.2015.05.002
  • Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia:
           Case Report and Literature Review
    • Authors: Neil B. Newman; Salma K. Jabbour, Jane Date C. Hon, Joseph J. Berman, Deen Malik, Darren Carpizo, Rebecca A. Moss
      First page: 163
      Abstract: Hepatocellular carcinoma (HCC) in non-cirrhotic livers is an uncommon finding and can present insidiously in patients. Another uncommon finding in HCC, and one of poor prognosis, is the presence of paraneoplastic diseases such as hypercalcemia. We report a case of a 66-year-old previous healthy Filipina woman who after routine laboratory evaluation was discovered to have hypercalcemia as the first sign of an advanced HCC without underlying cirrhosis. Because of the patient's relative lack of symptoms, healthy liver function, lack of classical HCC risk factors, and unexpected hypercalcemia, the diagnosis of a paraneoplastic syndrome caused by a noncirrhotic HCC was unanticipated.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-04-28
      DOI: 10.1016/j.jceh.2015.04.001
  • A Tender Pulsatile Mass in a Patient with Splenomegaly
    • Authors: Madhu M.P; Bir Singh, Rupesh Pokharna, Garima Sharma, Gyan P. Rai
      First page: 167
      Abstract: A 30-years-old lady having lump in left upper abdomen for 10 years and now she presented with severe pain in same area with radiation to left shoulder for 1 week. Clinical examination revealed pallor, icterus, massive splenomegaly and a tender pulsatile lump of size 6×6 cm adjacent to spleen with a bruit.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-06-04
      DOI: 10.1016/j.jceh.2015.04.006
  • Recurrent Budd-Chiari Syndrome Presenting with Lower Limb Ulcers
    • Authors: Xingshun Qi; Feifei Wu, Daiming Fan, Guohong Han
      First page: 179
      Abstract: In China, most of BCS patients live in poverty so that the early diagnosis and appropriate treatments are delayed. They often has a chronic course with abdominal wall varices and lower limb edema.1 In the present case, lower limb edema is the first sign of recurrent BCS, which primarily results from the obstacle of venous return of the legs, and then it slowly progresses into the stagnant ulcer of lower limbs.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-05-11
      DOI: 10.1016/j.jceh.2015.04.005
  • Could Stem Cell Therapy be the Cure in Liver Cirrhosis'
    • Authors: Ahmer Irfan; Irfan Ahmed
      Pages: 142 - 146
      Abstract: Over the past five decades, liver cirrhosis has become an increasingly prevalent disease and one that will often require considerable medical intervention. However, current treatment options have demonstrated severe problems that have prompted research to provide a suitable alternative. These treatments are scarcely available, very expensive and present at a huge cost to the patient's quality of life. The introduction of stem cell therapy into liver disease has been heralded as the future of personalized medicine and may be the alternative that the healthcare system desperately seeks.
      Citation: Journal of Clinical and Experimental Hepatology 5, 2 (2015)
      PubDate: 2014-03-31
      DOI: 10.1016/j.jceh.2014.03.042
      Issue No: Vol. 5, No. 2 (2014)
  • Acute Portal Vein Thrombosis, No Longer a Contraindication for
           Transjugular Intrahepatic Porto-Systemic Shunt (TIPS) Insertion
    • Authors: Suraj Mammen; Shyamkumar N. Keshava, Sajith Kattiparambil
      Abstract: Portal vein thrombosis, once considered as a contraindication to transjugular intrahepatic porto-systemic shunt (TIPS) is now considered as an indication. We report a case with clinical and technical success in a patient with Budd Chiari syndrome and acute portal venous thrombosis. Though it is a well-established option, with the best of our knowledge, we could not find a report from India.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-20
      DOI: 10.1016/j.jceh.2014.08.008
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015